EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages

Vinod Nadella iD, Anu Sharma

International Journal of Molecular Sciences · 28.01.2026 · 27 (3) · 1292

DOI: 10.3390/ijms27031292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.01.2026. Verfasst von Vinod Nadella und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Host Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38103, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Macrophages, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-engineered immune cell therapies have revolutionized cancer treatment, with CAR-T cells demonstrating remarkable efficacy against hematological malignancies. However, the effectiveness of CAR-T and other lymphocyte-based therapies against solid tumors remains limited, primarily due to the immunosuppressive tumor microenvironment and poor infiltration of effector cells. Recently, CAR-macrophage (CAR-M) immunotherapy has emerged as a promising strategy to overcome these barriers. Leveraging the innate tumor-homing ability, phagocytic function, and antigen-presenting capacity of macrophages, CAR-M therapies offer unique advantages for targeting solid tumors. This review provides a comprehensive overview of the development and current state of CAR-Macrophage immunotherapy, including advances in CAR design and macrophage engineering, preclinical and clinical progress, and mechanistic insights into their anti-tumor activity. The review critically examined both the benefits and limitations of CAR-M approaches, addressing persistent challenges such as cell sourcing, durability, and safety, while also exploring innovative strategies to enhance therapeutic efficacy. Finally, future perspectives and the potential clinical impact of CAR-macrophage therapies were outlined, underscoring their emerging role in the evolving landscape of cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenMacrophagesNeoplasmsImmunotherapy, AdoptiveImmunotherapyHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

cancercell therapy engineeringchimeric antigen receptorimmunotherapymacrophagessolid tumorstumor microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Host Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.

ORCID-Profile: Vinod Nadella

Zitieren

APA

Nadella, V., & Sharma, A. (2026). Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages. International Journal of Molecular Sciences, 27(3), 1292. https://doi.org/10.3390/ijms27031292

Vancouver

Nadella V, Sharma A. Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages. International Journal of Molecular Sciences. 2026;27(3):1292. doi:10.3390/ijms27031292

BibTeX
@article{Nadella2026,
  author = {Nadella, Vinod and Sharma, Anu},
  title = {Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {3},
  pages = {1292},
  doi = {10.3390/ijms27031292}
}
Kostenlos starten →